Switch theme
Sign up to access all valuation multiples
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
2011
25
Last FY Revenue n/a
LTM EBITDA -$44.9M
$13.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tempest Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$44.9M.
In the most recent fiscal year, Tempest Therapeutics achieved revenue of n/a and an EBITDA of -$40.1M.
Tempest Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tempest Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$44.9M | XXX | -$40.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$40.6M | XXX | -$42.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$40.3M | XXX | -$41.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tempest Therapeutics's stock price is $6.
Tempest Therapeutics has current market cap of $22.1M, and EV of $13.7M.
See Tempest Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.7M | $22.1M | XXX | XXX | XXX | XXX | $-15.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tempest Therapeutics has market cap of $22.1M and EV of $13.7M.
Tempest Therapeutics's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Tempest Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tempest Therapeutics has a P/E ratio of -0.5x.
See valuation multiples for Tempest Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22.1M | XXX | $22.1M | XXX | XXX | XXX |
| EV (current) | $13.7M | XXX | $13.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTempest Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Tempest Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tempest Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tempest Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tempest Therapeutics acquired XXX companies to date.
Last acquisition by Tempest Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Tempest Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tempest Therapeutics founded? | Tempest Therapeutics was founded in 2011. |
| Where is Tempest Therapeutics headquartered? | Tempest Therapeutics is headquartered in United States of America. |
| How many employees does Tempest Therapeutics have? | As of today, Tempest Therapeutics has 25 employees. |
| Who is the CEO of Tempest Therapeutics? | Tempest Therapeutics's CEO is Mr. Stephen R. Brady. |
| Is Tempest Therapeutics publicy listed? | Yes, Tempest Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Tempest Therapeutics? | Tempest Therapeutics trades under TPST ticker. |
| When did Tempest Therapeutics go public? | Tempest Therapeutics went public in 2021. |
| Who are competitors of Tempest Therapeutics? | Similar companies to Tempest Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tempest Therapeutics? | Tempest Therapeutics's current market cap is $22.1M |
| Is Tempest Therapeutics profitable? | Yes, Tempest Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tempest Therapeutics? | Tempest Therapeutics's last 12 months EBITDA is -$44.9M. |
| What is the current EV/EBITDA multiple of Tempest Therapeutics? | Current EBITDA multiple of Tempest Therapeutics is -0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
